Takeda Pharmaceutical Co Ltd ADR Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR asset resilience ratio. Takeda Pharmaceutical Co Ltd ADR (TAK) has an Asset Resilience Ratio of 4.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TAK days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Takeda Pharmaceutical Co Ltd ADR (2001–2025)
Asset resilience ratio of Takeda Pharmaceutical Co Ltd ADR from 2001 to 2025. This chart shows how Takeda Pharmaceutical Co Ltd ADR's Asset Resilience Ratio has changed over time. Read Takeda Pharmaceutical Co Ltd ADR (TAK) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Takeda Pharmaceutical Co Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TAK total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $654.94 Billion | 4.25% |
| Short-term Investments | $107.00 Billion | 0.69% |
| Total Liquid Assets | $761.94 Billion | 4.94% |
Asset Resilience Insights
- Limited Liquidity: Takeda Pharmaceutical Co Ltd ADR maintains only 4.94% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Takeda Pharmaceutical Co Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Takeda Pharmaceutical Co Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Takeda Pharmaceutical Co Ltd ADR Asset Resilience Ratio by Year (2001–2025)
Takeda Pharmaceutical Co Ltd ADR asset resilience ratio by year from 2001 to 2025. The table below shows the annual Asset Resilience Ratio data for Takeda Pharmaceutical Co Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.78% | $254.22 Billion | $14.25 Trillion | +0.33pp |
| 2024-03-31 | 1.46% | $220.28 Billion | $15.11 Trillion | -2.51pp |
| 2023-03-31 | 3.97% | $553.70 Billion | $13.96 Trillion | +0.82pp |
| 2022-03-31 | 3.14% | $414.36 Billion | $13.18 Trillion | +0.27pp |
| 2021-03-31 | 2.88% | $371.62 Billion | $12.91 Trillion | +1.28pp |
| 2020-03-31 | 1.59% | $204.46 Billion | $12.82 Trillion | -1.91pp |
| 2019-03-31 | 3.50% | $486.17 Billion | $13.87 Trillion | -4.38pp |
| 2018-03-31 | 7.89% | $323.97 Billion | $4.11 Trillion | +0.19pp |
| 2017-03-31 | 7.69% | $335.17 Billion | $4.36 Trillion | +4.85pp |
| 2016-03-31 | 2.84% | $108.60 Billion | $3.82 Trillion | +1.41pp |
| 2015-03-31 | 1.43% | $61.27 Billion | $4.30 Trillion | -2.62pp |
| 2014-03-31 | 4.05% | $184.98 Billion | $4.57 Trillion | +3.64pp |
| 2013-03-31 | 0.41% | $16.24 Billion | $3.96 Trillion | +0.24pp |
| 2012-03-31 | 0.18% | $6.27 Billion | $3.58 Trillion | +0.12pp |
| 2011-03-31 | 0.05% | $1.51 Billion | $2.79 Trillion | -21.79pp |
| 2010-03-31 | 21.84% | $616.68 Billion | $2.82 Trillion | +2.67pp |
| 2009-03-31 | 19.17% | $529.25 Billion | $2.76 Trillion | -31.56pp |
| 2008-03-31 | 50.73% | $1.45 Trillion | $2.85 Trillion | +45.78pp |
| 2007-03-31 | 4.95% | $152.24 Billion | $3.07 Trillion | -3.04pp |
| 2006-03-31 | 8.00% | $243.28 Billion | $3.04 Trillion | -2.13pp |
| 2005-03-31 | 10.13% | $257.80 Billion | $2.55 Trillion | -0.22pp |
| 2004-03-31 | 10.35% | $241.67 Billion | $2.34 Trillion | +4.60pp |
| 2003-03-31 | 5.75% | $118.43 Billion | $2.06 Trillion | -3.81pp |
| 2002-03-31 | 9.56% | $187.89 Billion | $1.97 Trillion | +4.47pp |
| 2001-03-31 | 5.10% | $89.06 Billion | $1.75 Trillion | -- |
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more